Company reports on productive interactions with FDA and preparations for launch of omidubicel, if approved, in advance of May 1 PDUFA date
Company outlines strategic restructuring, plans to prioritize omidubicel launch and reduce operating expenses to extend cash runway
Company to explore strategic options to support a broader launch of omidubicel, including potential US and global partnerships with pharmaceutical companies
Company intends to continue GDA-201 Phase 1 study, discontinue development of natural killer (NK) cell preclinical candidates and consolidate its operations in Israel in Kiryat Gat
Company to host conference call at 8:00 am ET today
2023 Financial Guidance
Gamida Cell expects its current cash and cash equivalents will support the company’s ongoing operating activities through the third quarter of 2023. This cash runway guidance is based on the company’s current operational plans and excludes any additional funding and any business development activities that may be undertaken.
Conference Call Information
Gamida Cell will host a conference call today, March 27, 2023, at 8:00 a.m. ET to discuss these financial results and company updates. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live conference call webcast can be accessed in the "Investors & Media" section of Gamida Cell’s website at www.gamida-cell.com. A webcast replay will be available approximately two hours after the event for approximately 30 days.
https://finance.yahoo.com/news/gamida-cell-reports-full-2022-110000509.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.